Co-Management of COVID-19 and Heart Failure During the COVID-19 Pandemic: Lessons Learned

Area of Science:

• Cardiology
• Infectious Diseases
• Public Health

Background:

• The COVID-19 pandemic has significantly impacted patients with chronic conditions, particularly heart failure (HF).
• Evidence suggests an interaction between COVID-19 and HF, affecting prognosis and disease severity.
• The prevalence of severe COVID-19 complications in HF patients with mild symptoms is not well-understood.

Purpose of the Study:

• To review current literature on COVID-19 in the heart failure population.
• To explore the associated morbidity, mortality, and healthcare system impacts.
• To stimulate discussion for improved, tailored care for co-infected patients.

Main Methods:

• Literature review of existing studies on COVID-19 and heart failure.
• Analysis of epidemiological data regarding hospitalization rates and outcomes.
• Examination of potential drug interactions between HF treatments and COVID-19 therapies.

Main Results:

• Patients with pre-existing HF are at higher risk for severe COVID-19 complications.
• Hospitalization rates for acute HF decreased during the pandemic.
• A lack of specific diagnostic algorithms for differentiating HF from COVID-19-induced acute respiratory distress syndrome (ARDS) is noted.
• Potential interactions between HF treatments and antiviral/anti-inflammatory drugs raise treatment strategy concerns.

Conclusions:

• A comprehensive understanding of COVID-19's impact on HF patients is crucial.
• There is a need for specific diagnostic tools and tailored treatment strategies.
• Further research and discussion are required to optimize care delivery for this vulnerable population.